Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Cerwenka 2016 Mol Cell Oncol"

From Bioblast
(Created page with "{{Publication |title=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538. |info=[https...")
Β 
Β 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
{{Publication
{{Publication
|title=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538. Β 
|title=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538.
|info=[https://www.ncbi.nlm.nih.gov/pubmed/27652323 PMID: 27652323]
|info=[https://www.ncbi.nlm.nih.gov/pubmed/27652323 PMID: 27652323]
|authors=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G
|authors=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G
|year=2016
|year=2016
|journal=Mol Cell Oncol
|journal=Mol Cell Oncol
|abstract=Targeting tumor glycolysis would hit the main energy source of cancer. We show that natural killer (NK) cells pursue this strategy by employing high mobility group box 1 (HMGB1) protein-a well-known proinflammatory cytokine-to specifically target glycolysis in cancer cells. This opens up new perspectives for cancer immunotherapy. Β 
|abstract=Targeting tumor glycolysis would hit the main energy source of cancer. We show that natural killer (NK) cells pursue this strategy by employing high mobility group box 1 (HMGB1) protein-a well-known proinflammatory cytokine-to specifically target glycolysis in cancer cells. This opens up new perspectives for cancer immunotherapy.
|keywords=Cancer, HMGB1, NK cells, Natural killer cells, Cell death, Immunotherapy, Innate immunity, Metabolism
|keywords=Cancer, HMGB1, NK cells, Natural killer cells, Cell death, Immunotherapy, Innate immunity, Metabolism, HT29 colon carcinoma cells
}}
}}
{{Labeling
{{Labeling
|area=Respiration
|area=Respiration
|diseases=Cancer
|diseases=Cancer
|tissues=Endothelial;epithelial;mesothelial cell
|organism=Human
|tissues=Endothelial;epithelial;mesothelial cell, Other cell lines
|instruments=Oxygraph-2k
|instruments=Oxygraph-2k
|additional=Labels, 2016-11
|additional=2016-11,
}}
}}

Latest revision as of 12:35, 9 November 2017

Publications in the MiPMap
Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538.

Β» PMID: 27652323

Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) Mol Cell Oncol

Abstract: Targeting tumor glycolysis would hit the main energy source of cancer. We show that natural killer (NK) cells pursue this strategy by employing high mobility group box 1 (HMGB1) protein-a well-known proinflammatory cytokine-to specifically target glycolysis in cancer cells. This opens up new perspectives for cancer immunotherapy. β€’ Keywords: Cancer, HMGB1, NK cells, Natural killer cells, Cell death, Immunotherapy, Innate immunity, Metabolism, HT29 colon carcinoma cells


Labels: MiParea: Respiration  Pathology: Cancer 

Organism: Human  Tissue;cell: Endothelial;epithelial;mesothelial cell, Other cell lines 



HRR: Oxygraph-2k 

2016-11